There are currently 4 active clinical trials seeking participants for Renal Failure research studies. The states with the highest number of trials for Renal Failure participants are California, England, New York and Florida.
Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH
Recruiting
The goal is to investigate the safety of the conditioning regimen, and its ability to induce donor/recipient lymphohematopoietic chimerism without Chimerism Transition Syndrome (CTS), which may result in donor-specific unresponsiveness (tolerance) to the renal allograft in the absence of maintenance immunosuppression.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/04/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Renal Failure
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
Recruiting
This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: AKDHC Marana Surgery Center, Marana, Arizona +6 locations
Conditions: Chronic Kidney Diseases, End Stage Renal Disease, Arteriovenous Fistula, Hemodialysis Access Failure, ESRD, Vascular Access Complication, Renal Failure, Catheter Complications, Catheter Dysfunction, Renal Insufficiency
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Recruiting
This phase II trial studies how well daratumumab-based therapy works in treating patients with newly diagnosed multiple myeloma with kidney failure. Daratumumab-based therapy includes daratumumab, bortezomib, dexamethasone, and thalidomide or lenalidomide. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Bortezomib is a drug that prevents myeloma cells from getting rid of their waste products, leading to being targeted for death. Dexame... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2023
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Plasma Cell Myeloma, Renal Failure
Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes
Recruiting
Sub-optimal transfer of clinical information during inter-hospital transfer (IHT, the transfer of patients between acute care hospitals) is common and can lead to patient harm. To address this problem, the investigators will use key stakeholder input to refine and implement an interoperable health information exchange platform that integrates with the electronic health record and improves the reliability of and access to necessary clinical information in three use cases involving transfer of pat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/18/2023
Locations: Brigham & Women's Hospital, Boston, Massachusetts
Conditions: Infections, Heart Failure, COPD Exacerbation, Asthma, Gastrointestinal Diseases, Cardiac Event, Arrythmia, Renal Failure, Renal Disease, Rheumatic Diseases, Urologic Diseases, Neurologic Disorder, Hematologic Diseases, Oncology Problem, Shock, Critical Illness